Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Jan;37(1):23–27. doi: 10.1038/bjc.1978.3

Immunoadherence and complement in cancer-bearing mice.

C Porta, M L Villa, E Clerici
PMCID: PMC2009489  PMID: 619956

Abstract

Shortly after grafting of Ehrlich ascites carcinoma cells, the serum of tumour-bearing mice loses the capacity to mediate immunoadherence phenomena, because of a sharp decrease in the concentration of C3b and C3d, while the cellular receptors for such factors are unaffected by tumour growth. It is suggested that complement is consumed through the alternative pathway which is activated during the inflammatory responses accompanying tumour growth.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BALTCH A. L., OSBORNE W., BUNN P. A., CANARILE L., HASSIRDJIAN A. Serum complement and bacteriophage neutralization titers in human infections, leukemias, and lymphomas. J Lab Clin Med. 1960 Oct;56:594–606. [PubMed] [Google Scholar]
  2. BOURDIN J. S., SARACINO R. T., LILLE I., GABAY F. ETUDE DES VARIATIONS DU TAUX DU COMPL'EMENT AU COURS DE LA CHIMIOTH'ERAPIE DES CANCERS. Acta Unio Int Contra Cancrum. 1964;20:411–415. [PubMed] [Google Scholar]
  3. Bentley C., Bitter-Suermann D., Hadding U., Brade V. In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages. Eur J Immunol. 1976 Jun;6(6):393–398. doi: 10.1002/eji.1830060604. [DOI] [PubMed] [Google Scholar]
  4. Clerici E., Bigi G., Garotta G., Porta C., Mocarelli P. T-cell precursors in mice bearing the Ehrlich ascites tumors. J Natl Cancer Inst. 1976 Mar;56(3):513–516. doi: 10.1093/jnci/56.3.513. [DOI] [PubMed] [Google Scholar]
  5. HARTVEIT F. THE COMPLEMENT CONTENT OF THE SERUM OF NORMAL AS OPPOSED TO TUMOUR BEARING MICE. Br J Cancer. 1964 Dec;18:714–720. doi: 10.1038/bjc.1964.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Irie K., Irie R. F., Morton D. L. Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science. 1974 Nov 1;186(4162):454–456. doi: 10.1126/science.186.4162.454. [DOI] [PubMed] [Google Scholar]
  7. Kassel R. L., Old L. J., Carswell E. A., Fiore N. C., Hardy W. D., Jr Serum-mediated leukemia cell destruction in AKR mice. J Exp Med. 1973 Oct 1;138(4):925–938. doi: 10.1084/jem.138.4.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lichtenfeld J. L., Wiernik P. H., Mardiney M. R., Jr, Zarco R. M. Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease, and sarcoma. Cancer Res. 1976 Oct;36(10):3678–3680. [PubMed] [Google Scholar]
  9. Mason D. W. The requirement for C3 receptors on the precursors of 19S and 7S antibody-forming cells. J Exp Med. 1976 May 1;143(5):1111–1121. doi: 10.1084/jem.143.5.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Segerling M., Ohanian S. H., Borsos T. Persistence of immunoglobulin and complement components C4 and C3 bound to guinea pig tumor cells. J Natl Cancer Inst. 1976 Jul;57(1):145–150. doi: 10.1093/jnci/57.1.145. [DOI] [PubMed] [Google Scholar]
  11. Silveira N. P., Mendes N. F., Tolnai M. E. Tissue localization of two populations of human lymphocytes distinguished by membrane receptors. J Immunol. 1972 May;108(5):1456–1460. [PubMed] [Google Scholar]
  12. Southam C. M., Siegel A. H. Serum levels of second component of complement in cancer patients. J Immunol. 1966 Sep;97(3):331–337. [PubMed] [Google Scholar]
  13. Ting C. C., Herberman R. B. Humoral host defense mechanisms against tumors. Int Rev Exp Pathol. 1976;15:93–152. [PubMed] [Google Scholar]
  14. Verhaegen H., De Cock W., De Cree J., Verbruggen F. Increase of serum complement levels in cancer patients with progressing tumors. Cancer. 1976 Oct;38(4):1608–1613. doi: 10.1002/1097-0142(197610)38:4<1608::aid-cncr2820380427>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  15. Yoshikawa S., Yamada K., Yoshida T. O. Serum complement level in patients with leukemia. Int J Cancer. 1969 Nov 15;4(6):845–851. doi: 10.1002/ijc.2910040613. [DOI] [PubMed] [Google Scholar]
  16. ZARCO R. M., FLORES E., RODRIGUEZ F. SERUM COMPLEMENT LEVELS IN HUMAN CANCER. J Philipp Med Assoc. 1964 Nov;40:839–846. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES